The editors of JAMA recognize the challenges, concerns, and frustration about the shortage of personal protective equipment (PPE) that is affecting the care of
Share this article
Share this article
SEATTLE, May 19, 2021 /PRNewswire/ OnQuality Pharmaceuticals ( OnQuality ), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced that abstracts for the NOVA-II clinical trial evaluating OnQuality s lead candidate, OQL011, have been selected for presentations at two upcoming meetings: a Trial in Progress poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021, and an oral presentation at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Annual Meeting, being held virtually from June 24-26, 2021. The abstracts for both presentations include an update on the ongoing Phase II clinical trial and are both titled A Study to Investigate OQL011 on VEGFR Inhibitor-Associated
OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011 at the 2021 ASCO and MASCC/ISOO Annual Meetings prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.